Last updated: February 15, 2026
What is NDC 72205-0137?
NDC 72205-0137 refers to a specific medication identified by its National Drug Code (NDC). Based on available disclosures, this code corresponds to Imfinzi (durvalumab), a monoclonal antibody used in cancer immunotherapy. It is approved predominantly for treating non-small cell lung cancer (NSCLC), bladder cancer, and other malignancies as per FDA indications.
Market Overview
Current Market Size:
- The global immunotherapy market was valued at approximately $125 billion in 2022 and is projected to grow at a CAGR of 12-15% through 2030 (MarketWatch).
- Durvalumab (Imfinzi) contributes significantly to this segment, with sales reflecting its status as a first- or second-line treatment in multiple indications.
Key Competitors:
| Drug Name |
Company |
Indications |
Market Position |
2022 Global Sales (USD) |
| Imfinzi |
AstraZeneca |
NSCLC, bladder cancer, SCLC |
Major player, first-line use in NSCLC |
~$3.4 billion |
| Keytruda |
Merck |
Multiple cancers (lung, melanoma, head & neck) |
Dominates immunotherapy market |
~$20 billion |
| Tecentriq |
Roche |
Small cell lung cancer, NSCLC |
Growing presence |
~$2.4 billion |
Revenue Drivers:
- FDA approvals for additional indications.
- Expanded line-up in combination therapies.
- Price trajectory driven by exclusive patent protection, market demand, and reimbursement policies.
Pricing Dynamics
Pricing in the United States:
- List price for Imfinzi varies per indication but generally ranges from $10,000 to $15,000 per dose.
- Typical treatment involves 4-6 doses per cycle, with regimens lasting several cycles. Total treatment courses can cost between $40,000 and $90,000 per patient.
Market Penetration & Reimbursement:
- Pricing is affected by payer negotiations and value-based agreements.
- Medicare and private insurers commonly reimburse between 85-100% of list price, depending on negotiated discounts.
International Price Variations:
| Region |
Typical Price Range (USD) |
Notes |
| Europe |
$8,000 - $12,000 per dose |
Prices lower due to negotiated discounts |
| Asia (Japan) |
$7,000 - $10,000 per dose |
Price controlled by local agencies |
| Latin America |
$5,000 - $8,000 per dose |
Significantly lower, market penetration varies |
Future Price Projections
Patent and Exclusivity:
- US patent expiry expected in 2029, after which biosimilar competition could lower prices.
- Current legally exclusive status up to 2029:
| Year |
Anticipated Impact |
Notes |
| 2024-2026 |
Continued price stability |
Limited biosimilar options, market exclusivity remains |
| 2027-2029 |
Price pressure begins |
Biosimilar development accelerates |
Potential Price Tipping Points:
- Entry of biosimilars may reduce per-dose cost by 30-50% within 2-3 years post-patent expiry.
- Price reductions could also stem from new competitive therapies or regulatory shifts.
Pricing Trends Forecast:
| Year |
Estimated Per Dose Cost (USD) |
Rationale |
| 2023 |
$10,000 - $15,000 |
Current pricing, high demand, patent protection |
| 2025 |
$9,000 - $13,000 |
Slight reduction with increased competition efforts |
| 2030 |
$7,000 - $10,000 |
Biosimilar market entry potentially drives prices down |
Business & Regulatory Factors Affecting Pricing
- FDA approvals for new indications can sustain or elevate prices.
- Reimbursement policies influence net prices. The Centers for Medicare & Medicaid Services (CMS) prioritize value-based pricing agreements.
- Patent challenges or delays in biosimilar approval could extend market exclusivity and maintain higher prices longer.
Key Takeaways
- The market for NDC 72205-0137 (durvalumab) is sizable and projected to grow, primarily driven by expanding indications and combination therapies.
- Current list prices are approximately $10,000 per dose in the US, with total treatment costs averaging between $40,000 and $90,000.
- Price competition from biosimilars may emerge starting in 2029, potentially reducing costs by up to 50%.
- International prices vary based on regional policies, often marked lower than US prices.
- Patent protection duration remains the primary determinant for future pricing, with estimates suggesting sustained high prices until at least 2029.
FAQs
1. What factors influence the pricing of durvalumab?
Pricing depends on patent protection, competition, reimbursement negotiations, indication expansion, and manufacturing costs.
2. How soon could biosimilars impact the cost of NDC 72205-0137?
Biosimilars are likely to gain FDA approval and market entry around 2029, with initial price reductions starting a year earlier in some regions.
3. Are there any upcoming indications for durvalumab that could affect its market?
Yes. Ongoing clinical trials target additional cancers and combination therapies, potentially expanding the addressable market.
4. How do international prices compare to US prices?
International prices generally remain lower, driven by regional pricing policies and negotiation leverage.
5. What is the impact of patent expiry on future drug prices?
Patent expiry typically leads to biosimilar entry, increasing competition and reducing prices, impacting profit margins accordingly.
Sources
- MarketWatch, "Global Immunotherapy Market Size," 2022.
- FDA, "Drug Approval Details for Durvalumab," 2017.
- IQVIA, "Prescription Drug Price & Market Insights," 2022.
- FDA, "Biosimilar Biological Products," 2023.
- Centers for Medicare & Medicaid Services, "Reimbursement Policies," 2022.
